​

Altimmune (ALT) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Altimmune Revenue Highlights

Latest Revenue (Y)

$426.00K

Latest Revenue (Q)

$5.00K

Main Segment (Y)

Grant

Main Geography (Y)

Grant

Altimmune Revenue by Period

Altimmune Revenue by Year

DateRevenueChange
2023-12-31$426.00K-726.47%
2022-12-31$-68.00K-101.54%
2021-12-31$4.41M-46.12%
2020-12-31$8.19M41.09%
2019-12-31$5.80M-43.85%
2018-12-31$10.33M24792.58%
2017-12-31$41.50K-99.21%
2016-12-31$5.23M-50.85%
2015-12-31$10.64M4.42%
2014-12-31$10.19M-43.11%
2013-12-31$17.91M-28.85%
2012-12-31$25.18M3.75%
2011-12-31$24.27M15.59%
2010-12-31$20.99M-23.80%
2009-12-31$27.55M-16.29%
2008-12-31$32.91M124.75%
2007-12-31$14.64M692.53%
2006-12-31$1.85M215.27%
2005-12-31$586.07K-

Altimmune generated $426.00K in revenue during NA 2023, up -726.47% compared to the previous quarter, and up 4.12% compared to the same period a year ago.

Altimmune Revenue by Quarter

DateRevenueChange
2024-06-30$5.00K-
2024-03-31$5.00K-86.49%
2023-12-31$37.00K-89.78%
2023-09-30$362.00K5933.33%
2023-06-30$6.00K-71.43%
2023-03-31$21.00K-119.09%
2022-12-31$-110.00K-5600.00%
2022-09-30$2.00K-75.00%
2022-06-30$8.00K-75.00%
2022-03-31$32.00K-99.02%
2021-12-31$3.28M1980.27%
2021-09-30$157.56K14.49%
2021-06-30$137.62K-83.57%
2021-03-31$837.52K-63.79%
2020-12-31$2.31M-21.28%
2020-09-30$2.94M307.13%
2020-06-30$721.64K-67.39%
2020-03-31$2.21M284.28%
2019-12-31$575.80K-10.59%
2019-09-30$643.98K-60.40%
2019-06-30$1.63M-44.98%
2019-03-31$2.96M14.17%
2018-12-31$2.59M-1.74%
2018-09-30$2.63M8.99%
2018-06-30$2.42M48849.78%
2018-03-31$4.94K-99.82%
2017-12-31$2.81M-38.83%
2017-09-30$4.59M92891.90%
2017-06-30$4.94K-99.39%
2017-03-31$804.07K-28.17%
2016-12-31$1.12M12.63%
2016-09-30$993.88K-52.92%
2016-06-30$2.11M109.93%
2016-03-31$1.01M-20.59%
2015-12-31$1.27M9.57%
2015-09-30$1.16M0.55%
2015-06-30$1.15M-83.74%
2015-03-31$7.07M287.05%
2014-12-31$1.83M89.75%
2014-09-30$962.45K-73.70%
2014-06-30$3.66M-2.23%
2014-03-31$3.74M2.42%
2013-12-31$3.65M4.75%
2013-09-30$3.49M-18.79%
2013-06-30$4.30M-33.66%
2013-03-31$6.48M7.67%
2012-12-31$6.01M-10.19%
2012-09-30$6.70M6.00%
2012-06-30$6.32M2.73%
2012-03-31$6.15M-1.45%
2011-12-31$6.24M18.62%
2011-09-30$5.26M-18.18%
2011-06-30$6.43M1.44%
2011-03-31$6.34M-7.53%
2010-12-31$6.85M9.78%
2010-09-30$6.24M30.63%
2010-06-30$4.78M53.36%
2010-03-31$3.12M-56.27%
2009-12-31$7.13M4.33%
2009-09-30$6.83M-15.37%
2009-06-30$8.07M46.17%
2009-03-31$5.52M0.76%
2008-12-31$5.48M-48.67%
2008-09-30$10.68M-2.18%
2008-06-30$10.91M86.88%
2008-03-31$5.84M-2.06%
2007-12-31$5.96M-

Altimmune generated $5.00K in revenue during Q2 2024, up 0.00% compared to the previous quarter, and up 23.81% compared to the same period a year ago.

Altimmune Revenue Breakdown

Altimmune Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 21Dec 20Dec 18
Grant$3.70M$3.10M$10.31M
License And Service--$19.78K

Altimmune's latest annual revenue breakdown by segment (product or service), as of Dec 21: Grant (100.00%).

Quarterly Revenue by Product

Product/ServiceDec 21Sep 21Jun 21Mar 21Dec 18Sep 18Jun 18
Grant$3.30M$100.00K$100.00K$200.00K$2.58M$2.63M$2.41M
License And Service----$4.95K--
License and Service-----$4.95K$4.95K

Altimmune's latest quarterly revenue breakdown by segment (product or service), as of Dec 21: Grant (100.00%).

Altimmune Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 21Dec 20Dec 18
Grant$3.70M$3.10M$10.31M
License And Service--$19.78K

Altimmune's latest annual revenue breakdown by geography, as of Dec 21: Grant (100.00%).

Quarterly Revenue by Country

CountryDec 21Sep 21Jun 21Mar 21Dec 18Sep 18Jun 18
Grant$3.30M$100.00K$100.00K$200.00K$2.58M$2.63M$2.41M
License And Service----$4.95K--
License and Service-----$4.95K$4.95K

Altimmune's latest quarterly revenue breakdown by geography, as of Dec 21: Grant (100.00%).

Altimmune Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ACADACADIA Pharmaceuticals$726.44M$250.40M
ARDXArdelyx$124.46M$98.24M
FBIOFortress Biotech$59.66M$14.63M
HOOKHOOKIPA Pharma$20.13M-
ALTAltimmune$426.00K$5.00K
VSTMVerastem-$10.00M
XFORX4 Pharmaceuticals-$560.00K
CABACabaletta Bio--
VKTXViking Therapeutics--
RVPHReviva Pharmaceuticals--
DAWNDay One Biopharmaceuticals-$20.07M
ZURAZura Bio--
INZYInozyme Pharma--
BIVIBioVie--
ATHAAthira Pharma--
SAVACassava Sciences--
CGTXCognition Therapeutics--
MDGLMadrigal Pharmaceuticals-$62.17M
TERNTerns Pharmaceuticals--
AKROAkero Therapeutics--
AVXLAnavex Life Sciences--
HEPAHepion Pharmaceuticals--
INMBINmune Bio$-155.00K-

ALT Revenue FAQ

What is Altimmune’s yearly revenue?

Altimmune's yearly revenue for 2023 was $426K, representing a decrease of -726.47% compared to 2022. The company's yearly revenue for 2022 was $-68K, representing a decrease of -101.54% compared to 2021. ALT's yearly revenue for 2021 was $4.41M, representing a decrease of -46.12% compared to 2020.

What is Altimmune’s quarterly revenue?

Altimmune's quarterly revenue for Q2 2024 was $5K, a 0% increase from the previous quarter (Q1 2024), and a -16.67% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $5K, a -86.49% decrease from the previous quarter (Q4 2023), and a -76.19% decrease year-over-year (Q1 2023). ALT's quarterly revenue for Q4 2023 was $37K, a -89.78% decrease from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).

What is Altimmune’s revenue growth rate?

Altimmune's revenue growth rate for the last 3 years (2021-2023) was -90.34%, and for the last 5 years (2019-2023) was -92.66%.

What are Altimmune’s revenue streams?

Altimmune's revenue streams in c 21 are Grant

What is Altimmune’s main source of revenue?

For the fiscal year ending Dec 21, the largest source of revenue of Altimmune was Grant. This segment made a revenue of $3.7M, representing 100.00% of the company's total revenue.